Chapter 15. Environmental Considerations in Biologics Manufacture

  1. Dr. Peter J. Dunn2,3,
  2. Dr. Andrew S. Wells4 and
  3. Dr. Michael T. Williams5
  1. Sa V. Ho

Published Online: 19 MAR 2010

DOI: 10.1002/9783527629688.ch15

Green Chemistry in the Pharmaceutical Industry

Green Chemistry in the Pharmaceutical Industry

How to Cite

Ho, S. V. (2010) Environmental Considerations in Biologics Manufacture, in Green Chemistry in the Pharmaceutical Industry (eds P. J. Dunn, A. S. Wells and M. T. Williams), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527629688.ch15

Editor Information

  1. 2

    Pfizer Green Chemistry Lead, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom

  2. 3

    Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK

  3. 4

    Astra Zeneca, Process Research & Development, Bakewell Road, Loughborough, LE11 5RH, United Kingdom

  4. 5

    CMC Consultant, 133, London Road, Deal, Kent, CT14 9TY, United Kingdom

Author Information

  1. Pfizer Global Biologics, 700 Chesterfield Parkway BB3D, Chesterfield, MO 63017, USA

Publication History

  1. Published Online: 19 MAR 2010
  2. Published Print: 10 MAR 2010

ISBN Information

Print ISBN: 9783527324187

Online ISBN: 9783527629688

SEARCH

Keywords:

  • therapeutic biologics;
  • peptides;
  • proteins;
  • nucleotides;
  • vaccines;
  • microbial production;
  • fermentation;
  • monoclonal antibodies;
  • Pharmaceutical Roundtable;
  • mammalian cell culture;
  • single-use equipment;
  • E factor, bioprocessing

Summary

This chapter contains sections titled:

  • Introduction

  • Therapeutic Biologics

  • Environmental Impact Considerations

  • Overall Comparison

  • Environmental Indices for Therapeutic Protein Manufacture

  • Technologies with Potential Environmental Impact

  • Single-Use Biologics Manufacture

  • Summary

  • Acknowledgments

  • References